Bristol Myers Squibb Acquires Mirati Therapeutics for $4.8 Billion October 10, 2023 US pharmaceutical giant Bristol Myers Squibb has acquired Mirati Therapeutics, a clinical-stage biotechnology company focussed on targeted oncology treatments, for $4.8 billion.
Page 1 of 1